45 completed, 16 terminated, 7 withdrawn, 6 active not recruiting. 48 Phase 2, 39 Phase 1, 2 Not applicable, 1 Early Phase 1.
Follow Refractory Plasma Cell Myeloma: new trials by email Literature Review of Refractory Plasma Cell Myeloma trials Research Report on Refractory Plasma Cell Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma Carfilzomib, Daratumumab, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 8 | 2022-12-08 | 2026-09-15 |
| Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma Actinium Ac 225-DOTA-Daratumumab, Daratumumab, Indium In 111-DOTA-Daratumumab - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2022-11-22 | 2025-10-29 |
| Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma Tocilizumab, Venetoclax - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Active not recruiting | Emory University | 7 | 2022-10-19 | 2026-02-17 |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | University of Southern California | 10 | 2022-10-07 | 2026-05-13 |
| Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol - Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Not applicable | Recruiting | Roswell Park Cancer Institute | 175 | 2022-06-28 | 2025-12-01 |
| Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma Autologous MUC1-activated T-cells, Cyclophosphamide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Active not recruiting | Mayo Clinic | 5 | 2022-06-20 | 2026-04-03 |
| Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma Carfilzomib, Isatuximab, Pomalidomide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 5 | 2022-06-14 | 2026-07-02 |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Pembrolizumab - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Terminated | Alfred Chung, MD | 3 | 2022-05-03 | 2025-01-15 |
| Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Terminated | Abdullah Khan | 1 | 2021-09-27 | 2024-06-06 |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma Belantamab Mafodotin, Daratumumab, Dexamethasone - Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Phase 1 | Terminated | Mayo Clinic | 5 | 2021-06-03 | 2025-05-18 |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma Choline Salicylate, Selinexor - Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma | Phase 1 | Completed | Mayo Clinic | 22 | 2021-02-08 | 2026-05-28 |
| Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab Azacitidine, Daratumumab, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | University of California, San Francisco | 5 | 2020-11-30 | 2024-04-30 |
| Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma Dexamethasone, Leflunomide, Pomalidomide - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Recruiting | City of Hope Medical Center | 29 | 2020-11-24 | 2026-05-29 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Completed | University of California, San Francisco | 23 | 2020-04-16 | 2023-08-21 | |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma Dexamethasone, Ixazomib, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-06-21 | 2019-03-26 | |
| CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma CS1-CAR T Therapy, Cyclophosphamide, Fludarabine - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Suspended | City of Hope Medical Center | 30 | 2019-04-23 | 2026-07-01 |
| Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma Bortezomib, Metformin Hydrochloride, Nelfinavir Mesylate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 9 | 2019-04-17 | 2024-08-22 |
| Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma Bortezomib, Daratumumab, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-01-25 | 2023-09-26 |
Showing 20 of 79. Sign in to see all of them.
Multiple Myeloma (79) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Hodgkin Disease (8) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Mantle-Cell (8) · Lymphoma, Non-Hodgkin (8) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Follicular (7) · Waldenstrom Macroglobulinemia (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Burkitt Lymphoma (4) · Hematologic Neoplasms (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Myeloid, Acute (4) · Leukemia, Plasma Cell (4)
Blood Protein Disorders (79) · Cardiovascular Diseases (79) · Hematologic Diseases (79) · Hemic and Lymphatic Diseases (79) · Hemorrhagic Disorders (79) · Hemostatic Disorders (79) · Immune System Diseases (79) · Immunoproliferative Disorders (79) · Lymphoproliferative Disorders (79) · Neoplasms by Histologic Type (79) · Neoplasms, Plasma Cell (79) · Paraproteinemias (79) · Vascular Diseases (79) · Neoplasms (78) · Lymphatic Diseases (17)
Calcium Dobesilate (26) · Dexamethasone (26) · auricularum (23) · dexamethasone 21-phosphate (23) · dexamethasone acetate (23) · Bortezomib (13) · Cyclophosphamide (13) · Melphalan (11) · Lenalidomide (10) · Peripheral Blood Stem Cell Transplantation (10) · Whole-Body Irradiation (8) · carfilzomib (8) · daratumumab (8) · fludarabine phosphate (8) · Mycophenolic Acid (7)
Mayo Clinic (16) · National Cancer Institute (NCI) (14) · Fred Hutchinson Cancer Center (9) · City of Hope Medical Center (8) · M.D. Anderson Cancer Center (7) · Emory University (3) · OHSU Knight Cancer Institute (3) · Albert Einstein College of Medicine (2) · Roswell Park Cancer Institute (2) · University of California, San Francisco (2) · University of Southern California (2) · University of Washington (2) · Abdullah Khan (1) · Academic and Community Cancer Research United (1) · Alfred Chung, MD (1)
United States (77) · Canada (1) · Denmark (1) · Germany (1)
Alfred Chung, MD (2) · Andrew Cowan (2) · Brenda Sandmaier (2) · Robert Orlowski (2) · Shaji K. Kumar, M.D. (2) · Shaji Kumar (2) · Sikander Ailawadhi, M.D. (2) · Abdullah M Khan, MBBS, MSc (1) · Amrita Krishnan (1) · Angela Dispenzieri (1) · Ashley Rosko, MD (1) · C. Babis Andreadis, MD (1) · Carol Huff (1) · Cesar Rodriguez (1)
PMID 32499241, PMID 25085357, PMID 27702799, PMID 28314788, PMID 29296873, PMID 31558469, PMID 31765263, PMID 32268821, PMID 32299820, PMID 32463741, PMID 32710011, PMID 34156440, PMID 35175355, PMID 36898933, PMID 37300573, PMID 37414012, PMID 37812476, PMID 38698840, PMID 38797190, PMID 39863139, PMID 40198877
P30CA015083 (9), P30CA015704 (7), U10CA180820 (4), P30CA013330 (3), P30CA016058 (3), P30CA016672 (3), P30CA138292 (3), U24CA196172 (3), N01CM00100 (2), P01CA018029 (2), P30CA014089 (2), P30CA076292 (2), UM1CA186644 (2), N01CM00032 (1), N01CM00071 (1)